1. Home
  2. KPTI vs PRE Comparison

KPTI vs PRE Comparison

Compare KPTI & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • PRE
  • Stock Information
  • Founded
  • KPTI 2008
  • PRE 2014
  • Country
  • KPTI United States
  • PRE Hong Kong
  • Employees
  • KPTI N/A
  • PRE N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • PRE Biotechnology: Laboratory Analytical Instruments
  • Sector
  • KPTI Health Care
  • PRE Industrials
  • Exchange
  • KPTI Nasdaq
  • PRE Nasdaq
  • Market Cap
  • KPTI 66.7M
  • PRE 69.7M
  • IPO Year
  • KPTI 2013
  • PRE N/A
  • Fundamental
  • Price
  • KPTI $7.53
  • PRE $4.49
  • Analyst Decision
  • KPTI Strong Buy
  • PRE Buy
  • Analyst Count
  • KPTI 5
  • PRE 1
  • Target Price
  • KPTI $61.00
  • PRE $9.00
  • AVG Volume (30 Days)
  • KPTI 144.0K
  • PRE 7.5K
  • Earning Date
  • KPTI 05-07-2025
  • PRE 03-31-2025
  • Dividend Yield
  • KPTI N/A
  • PRE N/A
  • EPS Growth
  • KPTI N/A
  • PRE N/A
  • EPS
  • KPTI N/A
  • PRE N/A
  • Revenue
  • KPTI $145,237,000.00
  • PRE $25,561,362.00
  • Revenue This Year
  • KPTI $4.37
  • PRE $51.43
  • Revenue Next Year
  • KPTI $19.07
  • PRE $131.29
  • P/E Ratio
  • KPTI N/A
  • PRE N/A
  • Revenue Growth
  • KPTI N/A
  • PRE N/A
  • 52 Week Low
  • KPTI $5.90
  • PRE $2.85
  • 52 Week High
  • KPTI $24.75
  • PRE $7.84
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.25
  • PRE 27.01
  • Support Level
  • KPTI $5.90
  • PRE $4.62
  • Resistance Level
  • KPTI $8.45
  • PRE $4.98
  • Average True Range (ATR)
  • KPTI 1.06
  • PRE 0.21
  • MACD
  • KPTI -0.01
  • PRE -0.06
  • Stochastic Oscillator
  • KPTI 36.38
  • PRE 17.05

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.

Share on Social Networks: